CHICAGO -- Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials. Mean sleep latency across four, 40-minute ...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and ...
Earlier this month, Alkermes plc announced that the FDA granted Breakthrough Therapy designation to alixorexton, its oral selective orexin 2 receptor agonist, for narcolepsy type 1 based on positive ...
STANS, Switzerland, May 18, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and ...
Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...
In a recent review published in the Nutrients Journal, researchers examined the current evidence of the intricate relationship between orexin, rapid eye movement (REM) sleep, and appetite. Study: ...
ACNP abstracts are available on the conference website and the Company’s poster will be available on the Centessa website at https://investors.centessa.com/events-presentations after the poster ...
Despite successful preclinical testing, 85% of early clinical trials for novel drugs fail. Most futilities originate from molecular mechanisms of the drug(s) tested. It is critically important to ...
(Philadelphia, PA) – Researchers at the University of Pennsylvania School of Medicine have discovered that the recently identified neurotransmitter orexin (also known as hypocretin) influences reward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback